CSRxP(@RxPricing):Despite the savings greater biosimilar competition can deliver, Big Pharma continues to game the system to block more affordable alternatives from reaching patients. Lawmakers should build on recent bipartisan work to advance bipartisan, market-based solutions. More from @Axios:

CSRxP

@RxPricing

CSRxP fosters a national dialogue focused on the pricing of new high-cost drug therapies and striking a balance between innovation and affordability.

加入 June 2014

976 正在關注 3.4K 粉絲

CSRxP@RxPricing

2026.09.28 20:45

Despite the savings greater biosimilar competition can deliver, Big Pharma continues to game the system to block more affordable alternatives from reaching patients. Lawmakers should build on recent bipartisan work to advance bipartisan, market-based solutions. More from @Axios: